The short version of peptide backbone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-24 and is reviewed periodically as new material appears.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Hygroscopic, seal promptly after opening |
| Long-term storage temperature | At or below minus 20 C | Protect from repeated freeze-thaw |
| Working solution stability | Hours when refrigerated | Use within the same working day |
| Primary purity method | Reversed-phase HPLC | Often paired with mass spectrometry |
| Aggregate measurement | Size-exclusion chromatography | Reports high-molecular-weight species |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
In mass spectrometry, matrix-assisted ionization (also inlet ionization) is a low fragmentation (soft) ionization technique which involves the transfer of particles of the analyte and matrix sample from atmospheric pressure (AP) to the heated inlet tube connecting the AP region to the vacuum of the mass analyzer. Initial ionization occurs as the pressure drops within the inlet tube. Inlet ionization is similar to electrospray ionization in that a reverse phase solvent system is used and the ions produced are highly charged, however a voltage or a laser is not always needed. It is a highly sensitive process for small and large molecules like peptides, proteins and lipids that can be coupled to a liquid chromatograph. Inlet ionization techniques can be used with an Orbitrap mass analyzer, Orbitrap fourier transform mass spectrometer, linear trap quadrupole and MALDI-TOF.
If the content of a single indispensable amino acid in the diet is less than the individual's requirement, then it will limit the utilization of other amino acids and thus prevent the normal rates of synthesis even when the total nitrogen intake level is adequate. Thus the "limiting amino acid" will determine the nutritional value of the total nitrogen or protein in the diet. Protein sources are thus rated by their limiting amino acids. Most people eat a varied diet with multiple sources of protein. Incomplete sources can complement each other and become complete when combined. Combining does not need to happen for every single meal: so long as the diet is varied and meets caloric needs, even vegans and vegetarians – people who tend to have more "incomplete protein" in their diet – can easily meet their amino acid needs. In other words, most people do not need to consider the completeness of proteins of single foods.
where ρf is the density of the fluid, Vdisp is the volume of the displaced body of liquid, and g is the gravitational acceleration at the location in question. If this volume of liquid is replaced by a solid body of exactly the same shape, the force the liquid exerts on it must be exactly the same as above. In other words, the "buoyancy force" on a submerged body is directed in the opposite direction to gravity and is equal in magnitude to
=== 2015 season and WADA appeal === On 20 April 2015, ASADA announced that it would not appeal the AFL Anti-Doping Tribunal's not-guilty verdicts. ASADA's decision then allowed the World Anti-Doping Agency (WADA) to initiate its own review and appeal, and it announced its intention to appeal on 11 May. The appeal was a de novo hearing of the charges in the Swiss headquartered Court of Arbitration for Sport (CAS). The players were permitted to continue playing throughout the appeal process. In the process of lodging its appeal, the CAS erroneously made public on its website the names of the players; the names were promptly removed, but the players' anonymity was for the first time compromised. On-field, Essendon's form deteriorated dramatically in 2015, attributed in part to the mental impact of the WADA appeal. The club held a 3–3 record before WADA announced its appeal, before finishing 15th with a record of 6–16. Hird resigned as coach with three weeks remaining in the season. Chairman Paul Little, after chairing the club since July 2013, also stepped down after the season, and was replaced by Lindsay Tanner. CAS began to hear WADA's appeal on 16 November 2015 in Sydney. CAS's panel of arbitrators comprised English barrister Michael Beloff QC, Belgian-based barrister Romano Subiotto QC and Australian barrister James Spigelman QC.
Sources: en.wikipedia.org
J. Lyons & Co. was a British restaurant chain store, food manufacturing, and hotel conglomerate founded in 1884 by Joseph Lyons and his brothers in law, Isidore and Montague Gluckstein. Lyons' first teashop opened in Piccadilly, London in 1894, and from 1909 they developed into a chain of teashops, with the firm becoming a staple of the High Street in the UK. At its peak the chain numbered around 200 cafes. The teashops provided for tea and coffee, with food choices consisting of hot dishes and sweets, cold dishes and sweets, and buns, cakes and rolls. Making their first cakes and pastries in 1894, several Lyons cake products are still available on grocers' shelves, including Lyons' treacle tart, Lyons' Bakewell tart, Lyons' Battenberg, and Lyons' trifle sponges, which are sold by Premier Foods. The company is also known for its pioneering use of computers in the office.
==== The "disorganized crime" and choice theses ==== One of the most important trends to emerge in criminological thinking about OC in recent years is the suggestion that it is not, in a formal sense, "organized" at all. Evidence includes lack of centralized control, absence of formal lines of communication, fragmented organizational structure. It is distinctively disorganized. For example, Seattle's crime network in the 1970s and 80s consisted of groups of businessmen, politicians and of law enforcement officers. They all had links to a national network via Meyer Lansky, who was powerful, but there was no evidence that Lansky or anyone else exercised centralized control over them. While some crime involved well-known criminal hierarchies in the city, criminal activity was not subject to central management by these hierarchies nor by other controlling groups, nor were activities limited to a finite number of objectives. The networks of criminals involved with the crimes did not exhibit organizational cohesion. Too much emphasis had been placed on the Mafia as controlling OC. The Mafia were certainly powerful but they "were part of a heterogeneous underworld, a network characterized by complex webs of relationships." OC groups were violent and aimed at making money but because of the lack of structure and fragmentation of objectives, they were "disorganized". Further studies showed neither bureaucracy nor kinship groups are the primary structure of organized crime; rather, the primary structures were found to lie in partnerships or a series of joint business ventures.
=== Basic research and translational preclinical animal model research === Jennette, in collaboration with Falk, and UNC faculty associates Hong Xiao and Peiqi Hu, and other faculty and trainees, made multiple discoveries about the cellular and molecular mechanisms that cause ANCA disease. He, Falk, and their research associates published the first demonstration that ANCA can activate neutrophils in vitro, and the first in vivo animal model confirming that ANCA antibodies cause glomerulonephritis by inducing glomerulonephritis and vasculitis in mice by intravenous injection of anti-MPO antibodies. This model has been used to make discoveries about the pathogenesis of ANCA disease, including the discovery of a key role for alternative complement pathway activation and C5a receptor engagement, which can be targeted by a novel small molecular inhibitor of C5a receptor (Avacopan). This approach to therapy was FDA-approved for patient care in 2021.
=== Thomson Medal Award (since 1985) === 2024 Jennifer S. Brodbelt 2022 Vicki Wysocki and Lidia Gall 2020 Alison E. Ashcroft 2014 Carol V. Robinson 2009 Catherine E. Costello and Catherine. C. Fenselau
=== Pharmacodynamics === Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase (unlike donepezil, which selectively inhibits acetylcholinesterase). It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain neurotransmitter acetylcholine.
Sources: en.wikipedia.org
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.
Reversed-phase high-performance liquid chromatography is the standard method for purity and related substances. It separates the main peak from deletion sequences and oxidation products. Mass spectrometry is frequently used alongside it to confirm molecular identity.
Aggregates, truncated sequences, and oxidation products receive the most attention. Size-exclusion chromatography covers aggregates, while reversed-phase methods resolve many chemical variants. Limits are set according to the route of administration and the expected exposure.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.